Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: An algorithm for the pre-emptive use of plerixafor

Leukemia and Lymphoma

Volumn 55, Issue 2, 2014, Pages 331-336

  Farina, Lucia ^a   Spina, Francesco ^a   Guidetti, Anna ^a,b   Longoni, Paolo ^a   Ravagnani, Fernando ^a   Dodero, Anna ^a   Montefusco, Vittorio ^a   Carlo Stella, Carmelo ^a,b,c   Corradini, Paolo ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Lymphoma; Myeloma; Stem cell mobilization

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; ARTICLE; BLOOD CELL; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CD34+ BLOOD CELL; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

ADULT; AGED; ALGORITHMS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84897960598     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.802783     Document Type: Article

References (28)

1. Pusic I, Jiang SY, Landua S, et al Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-1056.
2. Tarella C, Di Nicola M, Caracciolo D, et al High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Bone Marrow Transplant 2002;30:725-732. (Pubitemid 36007752)
3. Wuchter P, Ran D, Bruckner T., et al Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010;16:490-499.
4. To LB, Levesque IP, Herbert KE How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011; 118:4530-4540.
5. Olivieri A, Marchetti M, Lemoli R., et al Proposed definition of "poor mobilizer" in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo italianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012;47:342-351.
6. Pierelli L, Perseghin P, Marchetti M., et al Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. Transfusion 2012;52:893-905.
7. DiPersio IF, Stadtmauer EA, Nademanee A, et al Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-5726.
8. DiPersio JF, Micallef IN, Stiff P.J., et al Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767-4773.
9. Calandra G, McCarty I, McGuirk I., et al AMD3100 plus G-CSF can successfully mobilize CD34 + cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41:331-338. (Pubitemid 351330727)
10. Duarte RF, Shaw BE, Marin P, et al Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011;46:52-58.
11. Worel N, Rosskopf K, Neumeister P., et al Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2011;51:968-975.
12. Hübel K., Fresen MM, Salwender H, et al Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011;46: 1045-1052.
13. Malard F, Kröger N, Gabriel I.H., et al Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 2012, 18:314-317.
14. Hübel K., Fresen MM, Apperley I.F., et al European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant 2012;47:1046-1050.
15. Arcaini L, Laszlo D, Rizzi S., et al Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience. Leuk Res 2011;35:712-714.
16. Broclebank AM, Sparrow RL Enumeration of the CD34 +cells in cord blood: a variation on a single-platform flow cytometric methos based on the ISHAGE gating strategy. Cytometry 2001;46: 254-261. (Pubitemid 32899797)
17. Alegre A, Tomás JF, Martínez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997;20:211-217. (Pubitemid 27361913)
18. Narayanasami U, Kanteti R, Morelli I., et al Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;98:2059-2064.
19. Dugan MI, Maziarz RT, Bensinger W.I., et al Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010;45:39-47.
20. Attolico I, Pavone V, Ostuni A., et al Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012;18:241-249.
21. Cavallo F, Bringhen S, Milone G., et al Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia 2011;25:1627-1631.
22. Pozotrigo M, Adel N, Landau H., et al Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone Marrow Transplant 2013 Jan 21. [Epub ahead of print]
23. Basak GW, Mikala G, Koristek Z., et al Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. Leuk Lymphoma 2011;52:1711-1719.
24. Jantunen E, Kuittmen T, Mahlamäki E, et al Efficacy of preemptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011; 86:299-304.
25. D'Addio A., Curti A, Worel N., et al The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011;46:356-363.
26. Costa LJ, Alexander ET, Hogan K.R., et al Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:64-69.
27. Horwitz ME, Chute JP, Gasparetto C, et al Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant 2012;47:1051-1055.
28. Jantunen E, Varmavuo V, Juutilainen A., et al Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Ann Hematol 2012;91: 1073-1079.